1. Introduction

Predictive genetic diagnostics refers to the use of genetic testing to identify whether an individual has an increased likelihood of developing a disease or medical condition in the future. Such testing may identify inherited mutations, disease susceptibility, carrier status, or genetic characteristics associated with particular health outcomes.

Examples include testing for BRCA1/BRCA2 variants associated with increased risks of breast and ovarian cancer, genetic testing for Huntington’s disease, and testing for inherited cardiovascular disorders.

The legal validity of predictive genetic diagnostics concerns whether these tests may lawfully be developed, marketed, prescribed, performed, interpreted, and used to make decisions about individuals.

The central legal question is:

When does the use of genetic information constitute legitimate preventive healthcare, and when does it become unlawful discrimination, a violation of privacy, or an infringement of individual autonomy?

The answer depends on several overlapping legal principles:

Informed consent and the right to refuse testing.

Privacy and confidentiality of genetic information.

Scientific validity and clinical utility.

Protection against genetic discrimination.

Regulation of laboratories, medical devices, and diagnostic services.

Reproductive autonomy and the rights of future children.

Liability for inaccurate results, negligent interpretation, or failure to disclose material risks.

Predictive genetic diagnostics are not inherently unlawful. Their validity generally depends on the applicable jurisdiction, the purpose of testing, the reliability of the method, the quality of consent, and the subsequent use of the results.

2. Meaning and legal nature of predictive genetic diagnostics

Predictive genetic diagnostics should be distinguished from ordinary diagnostic testing.

A genetic result does not necessarily establish that a disease will develop. A pathogenic variant may indicate a high risk without certainty, while a negative result may not eliminate the possibility of disease.

Consequently, the legal validity of a predictive test is different from the legal validity of a decision made using its result. A scientifically valid test may be used unlawfully by an employer, insurer, healthcare provider or public authority.

3. Principal legal requirements

A. Informed consent

Genetic testing can reveal information not only about the individual tested but also about biological relatives. It may uncover unexpected parentage, inherited disease risks or information relevant to future reproductive decisions.

Valid consent should ordinarily explain:

The purpose and scope of the test.

The condition or risk being investigated.

The limits of accuracy and the possibility of uncertain results.

Whether incidental findings may be disclosed.

Who will receive the results and how long samples or data will be retained.

Whether the sample or data may be used for research or commercial purposes.

The availability of genetic counselling and the right to decline testing.

Consent to medical treatment should not automatically be treated as consent to unrelated genetic research, commercial licensing or disclosure to an employer.

In Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1, the Supreme Court of India examined informed consent in the context of medical treatment. It stressed the importance of consent to the particular procedure and rejected the idea that consent to one intervention automatically authorises a materially different intervention.

Application: A patient who consents to genetic testing to guide cancer prevention has not necessarily consented to the use of the same information for employment screening or commercial profiling.

The case did not concern genetic testing directly, but its consent principles are highly relevant by analogy.

Indian Kanoon

B. Scientific validity and clinical utility

A predictive genetic diagnostic should have a defensible scientific basis.

Two distinct questions arise:

Analytical validity: Does the test reliably detect the genetic variant it claims to detect?

Clinical validity: Does the detected variant meaningfully predict the condition or outcome being assessed?

Clinical utility is an additional consideration: will the result help improve prevention, diagnosis, treatment or another legitimate healthcare outcome?

These standards are particularly important for direct-to-consumer genetic tests and complex risk scores. A test may accurately identify a variant but overstate its importance for a particular patient.

For example, reporting that a person has a genetic variant associated with a higher risk of cardiovascular disease does not establish that the person will develop that disease. Environmental factors, other genes, age and lifestyle may materially affect the outcome.

Where a laboratory or provider makes misleading claims, fails to validate a test adequately, or negligently interprets a result, possible consequences include professional discipline, regulatory action, consumer-protection proceedings and civil liability, depending on the applicable law.

C. Privacy and confidentiality

Genetic information can be unusually revealing because it may remain relevant throughout a person's life and disclose information about biological relatives.

The legal issues include:

Collection without valid authority.

Disclosure to third parties without an appropriate legal basis.

Unauthorised secondary use.

Inadequate data security.

Retention of samples beyond the stated purpose.

Re-identification of supposedly anonymised genomic data.

The appropriate legal standard depends on the jurisdiction and the context. Research, public-health surveillance, clinical care and commercial testing may be subject to different rules.

D. Non-discrimination

Predictive testing becomes particularly controversial when it is used to assess a person's future economic value rather than their present capabilities or actual health needs.

Examples include rejecting an otherwise qualified applicant because of a genetic predisposition, charging an individual more for insurance because of an elevated future risk, or denying access to a service based on an unvalidated risk score.

The legal position differs across countries. Some jurisdictions expressly prohibit certain forms of genetic discrimination, while others rely on general privacy, equality, disability, consumer-protection or employment laws.

4. Important case laws

The following judgments provide important principles for analysing the legality of predictive genetic diagnostics. Some concern genetic testing directly; others establish constitutional, medical-consent or patent principles that apply by analogy.

Case 1: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

Facts and issue: A nine-judge Bench considered whether privacy is a fundamental right under the Indian Constitution.

Judgment: The Court unanimously recognised privacy as a constitutionally protected right, including as an aspect of Article 21 and the freedoms guaranteed by Part III of the Constitution. The judgment also addressed informational privacy, dignity and individual autonomy.

Indian Kanoon+1

Application to predictive genetic diagnostics:

Genetic information may attract constitutional privacy protection.

State-mandated collection or use of genetic information must satisfy applicable constitutional requirements.

Intrusive measures require a lawful basis, a legitimate aim and proportionality.

Unnecessary disclosure or collection of genomic data may raise serious privacy concerns.

Legal significance: This is a foundational Indian constitutional authority for assessing compulsory genetic testing, genomic databases and the use of predictive genetic information by public authorities.

The judgment does not specifically decide the legality of predictive genetic diagnostics, so its application to those technologies requires interpretation of its general principles.

Case 2: Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India · (2008) 2 SCC 1

Facts: A patient underwent a diagnostic procedure but was subsequently subjected to more extensive surgery without her own informed consent.

Judgment: The Supreme Court examined the requirements of valid medical consent and the limits of the authority conferred by consent to a particular procedure.

Indian Kanoon

Application:

A provider conducting predictive genetic testing should explain the relevant procedure and its material implications. Consent to a clinical test should not automatically be interpreted as authorisation for unrelated genetic research, commercial use or disclosure.

Legal significance: The case supports the principle that consent must be meaningful and appropriately related to the intervention. It is relevant by analogy rather than a direct ruling on genetic testing.

Case 3: Suchita Srivastava v. Chandigarh Administration (2009)

Supreme Court of India · (2009) 9 SCC 1

Legal principle: The Court recognised reproductive choice as an aspect of personal liberty under Article 21, including the ability to make decisions concerning reproduction, subject to the applicable legal framework.

Application:

Predictive genetic diagnostics may influence decisions concerning pregnancy, embryo testing, reproductive planning and the risk of transmitting inherited conditions.

The judgment supports careful protection of reproductive autonomy. A genetic risk result should not, by itself, be treated as legal authority to compel a reproductive decision.

Legal significance: It provides a constitutional foundation for protecting personal reproductive decisions informed by genetic testing, although the case did not directly concern genomic diagnostics.

Case 4: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Supreme Court of the United States · 569 U.S. 576

Facts: Myriad Genetics identified the BRCA1 and BRCA2 gene sequences and developed tests used to assess the risk of breast and ovarian cancer. The dispute concerned patents over those genes and related DNA sequences.

Judgment: The Court held that naturally occurring DNA segments were not patent-eligible merely because they had been isolated. It distinguished laboratory-created complementary DNA (cDNA), which was generally patent-eligible under the circumstances considered. The judgment did not resolve every question concerning patentable diagnostic methods.

Justia U.S. Supreme Court Center

Application:

Discovering a natural genetic sequence does not necessarily establish ownership of the sequence itself.

Patent eligibility for an invention associated with genetic testing is distinct from the legality of performing the test.

A test may raise separate questions of scientific reliability, consent, clinical responsibility and data protection even when its technology is patentable.

Legal significance: This is an important comparative authority on the relationship between genetic discoveries, diagnostic innovation and intellectual-property rights. It is binding in the United States, not India.

Case 5: Mayo Collaborative Services v. Prometheus Laboratories, Inc. (2012)

Supreme Court of the United States · 566 U.S. 66

Legal principle: The Court rejected the relevant patent claims concerning methods of adjusting drug dosages based on metabolite levels because they impermissibly claimed natural relationships combined with conventional steps.

Application: Diagnostic inventions based on natural biological correlations may face patent-eligibility limitations even when the underlying correlations have substantial medical value.

Legal significance: The decision concerns patent eligibility, not whether a diagnostic test is clinically safe, medically appropriate or lawful to offer.

Case 6: Greenberg v. Miami Children's Hospital Research Institute, Inc. (2003)

United States Court of Appeals for the Eleventh Circuit · 264 F.3d 1062

Facts: Families and organisations contributed samples and information to research concerning Canavan disease. A dispute arose over the subsequent patenting and use of the research results.

Legal principle: The litigation considered informed consent, research contributions, fiduciary duties and conversion claims concerning biological materials and discoveries.

Application: Where genetic samples are collected for research, the original purpose, consent documents, representations made to participants and later uses of the findings may have legal significance.

Legal significance: The case illustrates the legal tensions between public-interest genetic research, participant expectations and commercialisation. It does not establish that all secondary uses of genetic data are unlawful.

Case 7: Gonzales v. Carhart (2007)

Supreme Court of the United States · 550 U.S. 124

This decision concerned restrictions on a particular abortion procedure and the constitutional treatment of abortion regulation in the United States at the time.

Its relevance to predictive genetic diagnostics is limited and contextual: prenatal genetic information can intersect with reproductive decisions and regulatory restrictions. The case is not a general ruling on the legality of prenatal genetic testing, and its historical legal framework must be distinguished from subsequent developments in United States abortion law.

Case 8: Havasupai Tribe v. Arizona Board of Regents (settlement in 2010)

Arizona, United States · Research-consent dispute

Facts: Members of the Havasupai Tribe challenged the use of blood samples supplied for diabetes research in other research projects, including studies involving ancestry and mental health.

The dispute was resolved through settlement rather than a definitive appellate judgment establishing a universal rule for genetic research.

Application: Consent to one research purpose should not casually be treated as consent to every later use of biological samples. Researchers should examine the scope of the original consent and the applicable rules governing secondary use.

Legal significance: The dispute is influential in discussions of genomic research ethics, collective interests, cultural sensitivity and the limits of broad research consent. It should not be cited as a binding judicial rule applicable to all jurisdictions.

5. Legal framework in India

India's legal framework for predictive genetic diagnostics is drawn from constitutional law, medical-consent principles, data-protection legislation, clinical regulation and rules governing particular forms of genetic testing.

A. Constitutional protection under Articles 14 and 21

Article 21 protects life and personal liberty, while Article 14 protects equality before the law and equal protection of the laws.

Together with Puttaswamy, these provisions may be relevant where predictive genetic information is collected, disclosed or used by the State in ways that affect personal autonomy, privacy or equality.

For example, a government programme that requires genetic testing for access to an ordinary public service could raise questions about legal authority, necessity, proportionality and discriminatory impact.

Article 14 does not automatically prohibit every distinction based on medical information. The legality of a particular distinction depends on its purpose, justification and applicable constitutional standards.

B. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023 provides a statutory framework for the processing of digital personal data. Genetic information linked to an identifiable individual may fall within the Act's general definition of personal data.

India Code+1

Important matters include:

Lawful grounds for processing personal data.

Notice and consent requirements where applicable.

Obligations concerning data security and processing.

Rights concerning access to information, correction and erasure, subject to the statutory framework.

Restrictions and exceptions that may apply to particular purposes or entities.

Commencement qualification: The Act has a phased commencement structure. The notification dated 13 November 2025 provides for the core provisions governing processing, including sections 3–17, to commence 18 months later, in May 2027. Accordingly, as of November 2026, those core provisions should not be assumed to be fully operative merely because the Act has been enacted.

India Code+1

The Act also does not establish a comprehensive, separate statutory code for genetic discrimination. The exact obligations applicable to a particular genetic-testing service must be assessed against the provisions in force at the relevant time and any other applicable law.

C. Medical negligence and consumer protection

A laboratory, clinician or diagnostic service may face legal consequences if it negligently performs or interprets a test, misrepresents its predictive power, or fails to communicate material limitations.

Potential issues include:

Sample mix-ups and laboratory errors.

Failure to recommend confirmatory testing where clinically indicated.

Misinterpretation of variants.

Failure to explain uncertain findings.

Incorrect advice concerning treatment or reproductive choices.

Failure to maintain confidentiality.

Liability depends on the applicable duty of care, breach, causation, harm and available legal defences. An inaccurate prediction does not automatically establish negligence, particularly when the test was properly performed and the uncertainty was adequately explained.

D. Prenatal testing and reproductive regulation

Prenatal genetic testing requires particular care because results may influence decisions affecting a pregnant person, a fetus and prospective parents.

India's Pre-Conception and Pre-Natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994 regulates specified diagnostic techniques and prohibits sex selection, subject to its detailed statutory scheme. It should not be interpreted as a blanket prohibition on all lawful medical genetic testing.

The legality of a prenatal test therefore depends on its purpose, the procedure used, the qualifications and registration of the relevant facility where required, and compliance with the applicable statutory restrictions.

6. Comparative legal position: United States

The United States has a more explicit statutory framework addressing certain forms of genetic discrimination.

The Genetic Information Nondiscrimination Act of 2008 (GINA) generally prohibits covered employers from discriminating on the basis of genetic information and restricts their acquisition and disclosure of such information. It also provides protections in specified health-insurance contexts.

U.S. Equal Employment Opportunity Commission+1

Important limitations remain:

GINA does not prohibit every possible form of genetic discrimination.

It does not generally extend its protections to life, disability or long-term-care insurance in the same way that it protects covered employment and health-insurance contexts.

Coverage, exceptions and additional state laws must be examined in each case.

For example, an employer covered by GINA generally cannot reject an otherwise qualified applicant simply because a predictive genetic test indicates an increased likelihood of developing a disease in the future.

The distinction is between a person's current ability to perform a job and a statistical prediction about future health. GINA generally prevents covered employers from using genetic information to make employment decisions.

U.S. Equal Employment Opportunity Commission+1

7. European legal approach

The European legal framework draws on human dignity, privacy, data protection, equality and medical-research safeguards.

The EU General Data Protection Regulation (GDPR) expressly includes genetic data within its definition of special categories of personal data. Article 9 generally prohibits processing such data unless an applicable exception is satisfied. The precise legal basis, safeguards and national rules depend on the circumstances.

Predictive genetic testing may also raise issues under the Council of Europe's Convention on Human Rights and Biomedicine (Oviedo Convention), particularly its provisions on consent, private life and genetic testing for health purposes, where applicable.

These frameworks demonstrate that lawful genetic testing requires more than technical capability: the collection, interpretation, disclosure and subsequent use of genetic information must also comply with applicable rights and safeguards.

8. When can predictive genetic diagnostics become unlawful?

The following examples illustrate the distinction between legitimate testing and potentially unlawful conduct.

The legal conclusion in each example depends on the applicable statute, the facts and any relevant exceptions.

9. Ethical and legal challenges

A. Probabilistic uncertainty

Genetic risk is often expressed as a probability rather than a certainty. Legal disputes may arise if providers fail to distinguish relative risk from absolute risk or imply that a genetic association establishes a definite outcome.

B. The right not to know

Some individuals may prefer not to learn about a future disease for which no effective prevention or treatment is available. This preference should be addressed during consent and counselling, subject to any applicable legal duties.

C. Family interests and confidentiality

A genetic result may reveal risks relevant to biological relatives. This creates tension between an individual's confidentiality and the possible interests of relatives in receiving clinically significant information.

There is no universal rule that relatives are automatically entitled to another person's genetic results. Disclosure must be assessed under applicable professional, privacy and legal standards.

D. Artificial intelligence and predictive scores

AI systems may combine genetic data with demographic, clinical and environmental variables. Their outputs can create additional concerns about bias, explainability, reproducibility and accountability.

A provider should not treat an algorithmic prediction as legally or medically conclusive merely because the system produces a numerical score.

10. Liability and remedies

Depending on the circumstances and jurisdiction, a person affected by unlawful predictive genetic testing or misuse of genetic information may be able to pursue one or more of the following:

Medical negligence proceedings for a breach of professional duty causing legally recognised harm.

Consumer-protection remedies for deficient services or misleading representations.

Data-protection complaints or remedies for unlawful processing, disclosure or inadequate security, where the relevant provisions are operative.

Constitutional remedies where State action violates fundamental rights.

Employment or equality claims where applicable law prohibits the discriminatory conduct.

Regulatory complaints concerning unapproved testing, professional misconduct or non-compliant laboratory practices.

Injunctive or other civil relief, where available, to restrain unlawful disclosure or use of genetic information.

The availability of compensation depends on the legal basis of the claim and proof of the required elements. A breach of consent or privacy does not necessarily produce the same remedy in every legal system.

11. A practical legal-validity test

A court, regulator or healthcare institution assessing a predictive genetic diagnostic can use the following analytical framework.

1. Lawful authority

Is the test permitted under the applicable healthcare, laboratory, research and data-protection rules?

2. Valid consent

Was the individual adequately informed and given a meaningful opportunity to accept or refuse testing?

3. Scientific reliability

Are the test method, interpretation and predictive claims supported by adequate evidence?

4. Privacy and data governance

Are collection, retention, sharing and secondary uses properly authorised and safeguarded?

5. Lawful downstream use

Is the result used for a legitimate purpose without prohibited discrimination or unjustified interference with individual rights?

Failure at one stage does not automatically invalidate every aspect of the test, but it may render a particular collection, procedure, disclosure or subsequent decision unlawful.

12. Conclusion

The legal validity of predictive genetic diagnostics rests on the relationship between medical innovation and fundamental rights. A test can be scientifically useful and legally permissible when appropriately validated, performed with valid consent, interpreted responsibly and used for a lawful purpose.

Conversely, scientific accuracy alone cannot justify compulsory testing, unauthorised disclosure, misleading medical claims or discriminatory decisions based on future disease risk.

In India, Puttaswamy provides the principal constitutional foundation for privacy and autonomy, while Samira Kohli supplies important consent principles. Comparative authorities such as Myriad Genetics clarify separate questions concerning intellectual property, and United States legislation such as GINA illustrates how genetic discrimination can be addressed through specific statutory protections.

The central legal principle is that the ability to predict a person's genetic risk does not, by itself, confer the right to control that person's choices, disclose their information or restrict their opportunities.

Scope note: This is a general legal analysis, not an opinion on a particular test or dispute. The precise outcome requires consideration of the relevant jurisdiction, the test's purpose, the evidence supporting its predictions and the legal rules in force at the time.